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Objective: Reconstruction of the pulmonary artery in association with lung resection is technically feasible with
low morbidity and mortality. To assess long-term outcome, we report our 20-year experience.
Methods: Between 1989 and 2008, we performed pulmonary artery reconstruction in 105 patients with non–
small cell lung cancer (tangential resections not included). Twenty-seven patients received induction therapy.
We performed 47 pulmonary artery sleeve resections, 55 reconstructions by pericardial patch (with 3 left pneu-
monectomies under cardiopulmonary bypass), and 3 by pericardial conduit. In 65 patients, a bronchial sleeve re-
section was associated; in 6 cases superior vena caval reconstruction was also required. Fifteen patients had stage
IB disease, 37 stage II, 31 IIIA, and 22 IIIB. Sixty-one patients had epidermoid carcinoma, and 38 adenocarci-
noma. Mean follow-up was 46  40 months.
Results: The procedure–related complications were 1 pulmonary artery thrombosis requiring completion pneu-
monectomy and 1 massive hemoptysis leading to death (operative mortality, 0.95%); 28 patients had other com-
plications, with the most frequent prolonged air leakage. Overall 5-year survival was 44%. Five- and 10-year
survivals for stages I and II versus stage III were, respectively, 60% versus 28% and 25% versus 12%. Five-
year survivals were 52.6% for N0 and N1 nodal involvement versus 20% for N2; 10-year survivals were
28% versus 3%. Multivariate analysis yielded induction therapy, N2 status, adenocarcinoma, and isolated pul-
monary artery reconstruction as negative prognostic factors.
Conclusions: Pulmonary artery reconstruction is safe, with excellent long-term survival. Our results support this
technique as an effective option for patients with lung cancer.G
T
SResection and reconstruction of the pulmonary artery (PA) is
considered feasible and safe for patients with non–small cell
lung cancer (NSCLC). This procedure is usually indicated
for tumors or satellite lymph nodes that involve the PA at
the lobar hilum and preclude complete resection by simple
lobectomy. The artery can be involved to various degrees,
from partial infiltration to a more extensive and even circum-
ferential invasion, although endovascular growth of the
tumor is rare. This heterogeneous presentation may require
either patch reconstruction, end–to–end anastomosis, or in-
terposition of a prosthetic conduit; simple tangential resec-
tion with direct suture traditionally is not included in the
domain of PA reconstruction by our group. The choice of
the most appropriate technique of reconstruction is usually
made at the time of surgery on the basis of the extent of
vascular involvement.
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pulmonary function is so compromised to preclude pneumo-
nectomy; in fact, at that time, the latter was the only proce-
dure considered appropriate to achieve cure in patients with
proximal lesions. It is now clear, however, that pneumonec-
tomy adds increased risk,1 especially when performed on the
right side and after induction chemotherapy,2 with deranged
cardiac function,3 worse quality of life,4 and decreased sur-
vival, particularly at early stages and in elderly patients.5,6
These considerations have led to a better evaluation of the
potentials of reconstructive procedures of the bronchus
and PA associated with lobectomy. It is now clear that bron-
chial sleeve resection is oncologically comparable to pneu-
monectomy, with the advantage of preserving pulmonary
function and decreasing morbidity and mortality.7-10 On
the vascular side, however, reconstructive procedures of
the PA have encountered more difficulty in gaining accep-
tance because of historical prejudices and lack of studies
on large and homogeneous series of patients with long-
term follow up. We therefore report here our 20-year expe-
rience with PA reconstruction alone or in association with
bronchial sleeve resection.
MATERIALS AND METHODS
From 1989 to 2008, we performed PA reconstruction on 105 consecutive
patients. The study was approved by the Institutional Review Board of the
University ‘‘Sapienza’’ of Rome. During this time, we performed a mean ofrdiovascular Surgery c Volume 138, Number 5 1185
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CPB ¼ cardiopulmonary bypass
CT ¼ computed tomography
NSCLC ¼ non–small cell lung cancer
PA ¼ pulmonary artery
5.25  1.9 PA reconstructions per year. This procedure accounted for
a mean of 3.6%  2.1% of the resections performed at our institution for
lung cancer; during the same period, 187 pneumonectomies were performed
(9.3  4.9 per year). Patients undergoing PA reconstruction before 1989
were not included in this study because they do not represent a homogeneous
population in terms of intraoperative and postoperative management. Tan-
gential resections of the PA were not included in this series because they
have not been considered as vascular reconstructions but rather as a simple
variation of standard lobectomy. Preoperative workup included total body
contrast CT, pulmonary function tests, blood gas analysis, cardiac evalua-
tion, and basic examinations as usual. Magnetic resonance imaging and pos-
itron emission tomography were performed in selected cases. Patients who
were anticipated to be able to tolerate pneumonectomy according to stan-
dard preoperative evaluation criteria were not excluded from consideration
for PA reconstruction. Patients who had biopsy–proven N2 disease received
neoadjuvant chemotherapy with a cisplatin-based regimen and were subse-
quently reassessed. Preoperative radiotherapy is not routinely used at our
center. The surgical technique for PA reconstruction and bronchial sleeve
lobectomy has been previously described11,12 and was uniform throughout
the study period. The only intraoperative management modification was re-
lated to intravenous heparin administration: from the initial 3000 to 5000
units previously reported,11 we moved to a dose of 1500 to 2000 units. Op-
erative morbidity and mortality were considered any event within 30 days of
surgery or during the same hospitalization. No patients were unavailable for
follow-up. The mean follow–up was 46 40 months (range 1–180 months);
median follow–up was 32 months.
Patients were followed up after surgery with serial chest radiographs for
the first 6 months. Contrast total body CT was performed every 6 months for
2 years and then yearly. Positron emission tomography with fludeoxyglu-
cose F 18 (INN fludeoxyglucose [F18]) has been included more recently
in selected cases.
Data were collected and stored with an Excel data base (Microsoft Corp,
Redmond, Wash). Quantitative variables were expressed as mean  SD,
whereas nominal variables were expressed binarily as presence (1) or ab-
sence (0) of the event. In the univariate analysis, qualitative variables
were analyzed with the Pearson c2 test or Fisher exact test as required. Mul-
tivariate analysis was performed by Cox regression on variables that showed
statistical significance at univariate analysis. Survival curves were plotted
with the Kaplan–Meier formula; the log-rank test was performed to compare
survival between different groups. The statistical analysis was performed
with the STATISTICA data analysis software system (version 7; StatSoft
Inc, Tulsa, Okla).
RESULTS
There were 87 men (83%) and 18 women (17%). The
mean age was 62  10.5 years. The mean preoperative
forced expiratory volume in 1 second was 76.1%  14%
predicted (median, 75.5%; range, 41%–104%). Seventy-
eight percent of the patients were current or former smokers.
Comorbidities were present in 36 patients (34.3%). The
most common were arterial hypertension (18 patients,
17%) and chronic obstructive pulmonary disease (8 pa-
tients, 8%); other comorbidities were previous myocardial1186 The Journal of Thoracic and Cardiovascular Sinfarction (6 patients, 17%), diabetes (4 patients, 11%),
gastric ulcer (2 patients, 6%), carotid stenosis (1 patient,
3%), cerebrovascular problems (2 patients, 3%), and favism
(1 patient, 3%). Induction chemotherapy was administered
in 23 patients (22%), whereas preoperative radiotherapy
was performed only in 4 (4%); all patients receiving induc-
tion were in stage III, with the exception of 3 patients re-
ferred to our center after 3 cycles of chemotherapy
administered elsewhere who were in stage IIB. Forty-two
patients (40%) received adjuvant therapy. Seventy-four pro-
cedures (70.5%) were performed on the left side and 31
(29.5%) on the right. We performed 47 PA sleeve resections
(44.8%), 55 (52.3%) reconstructions by a pericardial patch
(3 associated with left pneumonectomy under cardiopulmo-
nary bypass [CPB]), and 3 (2.9%) by interposition of
a pericardial conduit. Patches were made with autologous
pericardium in 47 patients (85.5%) and with bovine pericar-
dium (Synovis Inc, Minneapolis, Minn) in 8 (14.5%). All
pericardial conduits were required on the left side; they
were made with autologous pericardium in 2 cases and bo-
vine pericardium in 1 and were prepared with the technique
previously described.12 The 3 patients undergoing pneumo-
nectomy and patch reconstruction under CPB received
induction radiotherapy. In 65 patients (62%), PA recon-
struction was associated with bronchial sleeve resection; in
all other cases it was associated with standard lobectomy,
with the exception of 1 patient undergoing bilobectomy.
The combined bronchovascular reconstructions were per-
formed on the left side in 45 cases (69.2%) and on the right
in 20 (30.7%). All patients underwent upper lobectomy (left
upper lobectomy most frequently at 72 patients, 69%), with
the exception of 2 who required left lower sleeve lobectomy
with reimplantation of the upper lobe. In all patients who
also underwent bronchial sleeve resection, an intercostal
muscle flap was wrapped around the bronchial anastomosis
to protect and revascularize the suture line and act as a buffer
between the vascular and bronchial repairs. In 6 cases supe-
rior vena cava reconstruction was also required: in 5 cases
the vessel was reconstructed with a graft (2 polytetrafluoro-
ethylene and 3 bovine pericardium tube) and in 1 case with
an autologous pericardium patch. Five of these patients
required a combined bronchovascular reconstruction. One
patient also underwent en bloc resection of the chest wall.
Fifteen patients (14.7%) were in stage IB, 37 (35.3%)
were in stage II (7 IIA and 30 IIB), 31 (29.5%) were in stage
IIIA, and 22 (20.9%) were in stage IIIB. Sixty-one patients
(58%) had epidermoid carcinoma, 38 (36.2%) had adeno-
carcinoma, 1 (0.9%) had mixed, and 5 (4.8%) had large
cell. One hundred one patients (96%) underwent complete
resection; in the last 53 procedures, only 1 patient (1.9%)
underwent incomplete resection.
Overall morbidity was 28.5% (30 patients). The proce-
dure–related major complications were 1 PA thrombosis
requiring completion pneumonectomy (postoperative dayurgery c November 2009
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massive hemoptysis leading to death (postoperative day 28);
the latter complication occurred in a patient undergoing
combined bronchovascular reconstruction. The operative
mortality was 0.95%. Twenty-eight patients (27%) had
other complications. The most frequent was prolonged air
leak (10 patients, 9.5%, 3 cases after induction chemother-
apy); other complications were atrial fibrillation (5 patients,
2 of whom had undergone patch reconstruction and pneu-
monectomy under CPB), empyema (3 patients, 2 after in-
duction chemotherapy), bronchopleural fistula (1 patient),
respiratory failure requiring noninvasive respiratory support
(1 patient), recurrent nerve paralysis (1 patient), pleural effu-
sion (1 patient), abdominal perforation and sepsis (1 patient),
and wound-related problems (5 patients). Overall, only 9
complications (30%) occurred in patients receiving induc-
tion therapy, without any statistically significant difference
(P ¼ .9). No PA obstruction or evidence of decreased flow
was detected with contrast CT performed during follow-up.
Patients undergoing pneumonectomy and patch recon-
struction under CPB survived 35 days (pneumonia after dis-
charge) and 25 and 36 months (both distant recurrences).
Because of the rarity of this procedure, these 3 patients
were excluded from survival analysis, which was therefore
performed on the remaining 102 patients.
Overall 5- and 10-year survivals were 44% and 20%,
respectively (Figure 1, A). The disease-free survivals (no re-
currence) were 43.1% at 5 years and 30.2% at 10 years (Fig-
ure 1, B). Patients in stage IB had 5- and 10-year survivals of
75% and 44% respectively; other survivals were 53% and
21% for stage II, 31% and 17% for stage IIIA, and 19%
and 6% for stage IIIB. There were no statistically significant
differences between stages IB and II (P ¼ .3) or between
stages IIIA and IIIB (P ¼ .5); for this reason, these stages
were considered in 2 groups (stages I and II vs stages IIIA
and IIIB) in the survival analysis. The 5- and 10-year sur-
vivals for stage I and II were 60% and 28%, respectively;
those for stage III were 25% and 12% (stages I and II vs
stages IIIA and IIIB, P¼ .004). The 5- and 10-year survivals
for squamous and nonsquamous carcinomas were 59.7%
versus 20.2% and 25% versus 13%. The N status had
a significant effect on survival: patients with N0 disease
had 5- and 10-year survivals of 67% and 33%, respectively.
For N1 disease, the 5- and 10-year survivals were 46% and
26%; for N2, they were 20% and 3%. There was no statis-
tical difference in survival between N0 and N1 disease at any
point (P¼ .5). For this reason, the 2 categories of N0 and N1
have been considered together in the survival analysis
(Figure 2), demonstrating the negative effect of N2 status.
There were 6 local recurrences (5.7%) and 40 distant recur-
rences (38%). Stage I and II lesions did not recur locally.
The 5-year survivals of patients undergoing isolated PA re-
construction and combined bronchovascular reconstruction
were 23% and 55,% respectively; at 10 years, they wereThe Journal of Thoracic and C7% and 30% (isolated PA vs combined P ¼ .01). Dis-
ease-free survivals for the same categories at 5 and 10 years
were respectively 45% versus 43% and 45% versus 27%
(P ¼ .9). Univariate analysis of overall survival (Table 1)
showed significant differences for stages I and II versus
stage III, induction versus noninduction therapy, PA recon-
struction alone versus combined bronchovascular recon-
struction, squamous versus nonsquamous histologic type,
N0 and N1 versus N2, and presence of complications and re-
currence versus none. A trend toward significance was seen
for patch reconstruction versus sleeve resection. At multi-
variate analysis (Table 2), only the diagnosis of adenocarci-
noma, N2 disease, administration of induction therapy, onset
of recurrence, and isolated PA reconstruction had confirmed
negative effects on outcome. Univariate and multivariate
analyses were repeated for disease-free survival; in those
analyses, isolated PA reconstruction did not show a negative
effect.
DISCUSSION
Complete surgical resection remains the cornerstone for
long-term survival of patients with NSCLC. With this intent,
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FIGURE 1. A, Overall survival. B, Disease-free survival.ardiovascular Surgery c Volume 138, Number 5 1187
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Spneumonectomy, when functionally feasible, has been con-
sidered for several decades to be the standard treatment for
central or locally advanced lesions. It is now clear, however,
that this operation entails increased morbidity and mortality
and is associated with a worse outcome. It should therefore
be performed only when no lesser resection is technically
feasible. This assumption has helped bronchial sleeve resec-
tion to gain progressively a stable position in the surgical
armamentarium. A number of studies initially supported
its feasibility and safety13 and subsequently also demon-
strated its functional and survival advantages relative to
pneumonectomy.7-10 A recent meta-analysis8 demonstrated
that parenchyma-sparing operations may reduce by 30%
the death risk relative to pneumonectomy and thus increase
survival, especially for patients with stages I and II NSCLC.
Despite the acceptance of bronchial reconstruction as an
oncologically reliable alternative to pneumonectomy inde-
pendent of the functional status of the patient, on the vascular
side the concept of PA reconstruction has encountered more
difficulties in gaining full acceptance. The potential risks
were initially overestimated because of historical concern
with this unfamiliar situation; the involvement of a low-pres-
sure system might hypothetically favor the onset of cata-
strophic intraoperative and postoperative complications.
The supposed requirement of full-dose heparinization, as
for other vascular procedures involving the systemic circula-
tion, might predispose toward hemorrhage or alternatively to
thrombosis of the anastomosis. The initial reports14-17 did not
alleviate this concern; on the contrary, this feeling was even
exacerbated by the high rate of PA thrombosis when tangen-
tial resection was performed.16,17 Major concerns were thus
initially related to feasibility, safety, long-term patency, and
effect on cardiopulmonary function; only later did oncologic
reliability and long-term survival come to the fore. With
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FIGURE 2. Survival by N status.1188 The Journal of Thoracic and Cardiovascular Surespect to the first two variables (feasibility and safety),
intraoperative and postoperative management and the
prevention and treatment of early complications have been
exhaustively addressed in the last decade (Table 3).7,18-24
Systemic heparinization has been reduced (1500 unites of
heparin intravenously in the last part of our series) to prevent
oozing from the sites of mediastinal lymphadenectomy.22
Heparin is not reversed with protamine at the end of the op-
eration, and subcutaneous low–molecular weight heparin is
administered according to the standard protocols for preven-
tion of pulmonary embolism. Long-term drug administration
to prevent clotting is not required if no other disorders coex-
ist. It has also been demonstrated that functional parameters
after PA reconstruction do not differ from those currently
reported for standard lobectomy.11 Echocardiography
has shown morphologic and dynamic patterns within the
TABLE 1. Univariate analysis for mortality
Total Alive Dead
Variable No. % No. % No. % P value
Sex .9
Male 86 84.3% 33 32.3% 53 52%
Female 16 15.7% 6 5.9% 10 9.8%
Age .5
65 y 51 50% 18 17.6% 33 32.3%
<65 y 51 50% 21 20.7% 30 29.4%
Stage .03
I or II 52 51% 25 24.5% 27 26.4%
III 50 49% 14 13.7% 36 35.2%
Induction .003
Yes 24 23.5% 3 2.9% 21 20.7%
No 78 76.5% 36 35.3% 42 41%
Reconstruction technique* .05
Patches 52 52.5% 16 16.1% 36 36.4%
Sleeves 47 47.5% 22 22.2% 25 25.3%
Procedure .009
PA alone 37 36% 8 7.8% 29 28.4%
PA with
bronchial sleeve
55 67% 31 30.4% 34 33.4%
Complications .007
Yes 30 29.4% 6 5.9% 24 23.5%
No 72 70.6% 33 32.4% 39 38.2%
Comorbidity .2
Yes 35 34.3% 16 15.7% 19 18.6%
No 67 65.7% 23 22.5% 44 43.2%
Recurrence .0004
Yes 46 45% 9 8.8% 37 36.3%
No 56 55% 30 29.4% 26 25.5%
Histologic type .04
Squamous 58 56.9% 27 26.4% 31 30.4%
Nonsquamous 44 43.1% 12 11.8% 32 31.4%
Nodal status .02
N0–N1 73 71.5% 33 32.3% 40 39.2%
N2 29 28.5% 6 5.9% 23 22.6%
PA, Pulmonary artery reconstruction. *Calculated on 99 patients; those undergoing
pneumonectomy (n ¼ 3) and tube reconstruction (n ¼ 3) were not included.rgery c November 2009
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Sreference range, with normal estimates of PA parameters in
96.2% of patients.11 Thrombosis is an exceptionally rare
event when true PA reconstruction is performed (0.95% in
our series), and an inappropriate tangential resection is
avoided when excessive reduction of the lumen is feared.
The oncologic reliability of PA reconstruction remains an
important issue to support the value of this procedure. It may
be more difficult to demonstrate definitively, however, be-
cause randomized trials comparing PA reconstruction with
pneumonectomy will probably never be possible. Long-
term survival analysis in a large, homogeneous series of pa-
tients could certainly help to support this technique. Only
a few studies to date have addressed this point, and these
have often included heterogeneous populations, including
tangential resection and true PA reconstruction (patch,
sleeve, conduit). In addition, survival has often been re-
ported in conjunction with bronchial sleeve resection, which
does not allow one to draw reliable conclusions.
Our series does not include tangential resection. We con-
sider vascular reconstruction to include only anatomic situ-
ations with gaps in the PA surface that must be filled with
a patch to avoid stenosis, circumferential resection with
end-to-end anastomosis, or conduit interposition. Simple
tangential resection has been advocated by other authors
when intraoperatively less than a quarter of the anterior
wall has to be resected.22,24 In such circumstances, we
make the same consideration, which also speeds dissection;
TABLE 2. Multivariate analysis performed by Cox regression
Variable $ SE P value Odds ratio
Stage (I–II/III) 0.2340 0.4231 .580
Induction (yes/no) -0.6876 0.3427 .04 0.623
Procedure (PA alone/PA with
bronchial sleeve resection)
-0.9798 0.2877 .0006 0.382
Complications (yes/no) 0.3237 0.2838 .254
Recurrence (yes/no) 0.6495 0.3275 .04 1.524
Histologic type
(nonsquamous/squamous)
-0.6616 0.2679 .01 0.644
Nodal status (N2/N0–N1) -0.8948 0.3846 .02 0.448
PA, Pulmonary artery reconstruction.The Journal of Thoracic and Chowever, this procedure should not be considered PA recon-
struction. Inclusion of tangential resections would have
greatly increased our numbers, but outcome analyses would
certainly have been less reliable.
Our long-term survival is in line with what can be ob-
tained for patients with NSCLC at similar stages who do
not require vascular reconstructions (stage IB, 76% and
44% at 5 and 10 years; stage II, 52% and 21%; stage III,
25% and 12%). The overall and disease-free survivals are
encouraging, and the local recurrence rate is low; however,
the N status, and in particular N2 disease, has a significant
effect on outcome, notwithstanding the administration of in-
duction and adjuvant therapy. This is still the most detrimen-
tal prognostic factor: 58.6% of patients with N2 disease had
distant metastases, and only 3% are alive at 10 years. This
aspect was already evident in our previous report11; for
this reason, the number of patients with N2 disease has sig-
nificantly decreased in our practice during the years (38%
until 1996 and 17% in the second part of our experience,
last 53 cases). Local recurrence was low at only 5.7% (all
patients with stage III NSCLC), confirming, along with the
high rate of complete resection, the oncologic value of the
procedure. In fact, this local recurrence rate is lower than
that seen in previous reports on PA reconstruction24 and
also lower than the overall rate among patients undergoing
standard resection.25 PA reconstruction can be performed
safely after induction chemotherapy, in line previously re-
ports for bronchial sleeve resection. In fact, the lower sur-
vival observed in this group of patients reflects the stage
of the tumor rather than the incidence of postoperative com-
plications.
One apparently new datum that surfaces from this
study and is somehow different from our previous re-
port11 is that combined bronchovascular reconstructions
may offer, from a purely statistical point of view, better
survival. This finding might elicit the conclusion that
combined reconstructions allow more radical resection.
If this were the case, however, there would have been
a larger number of local recurrences in the group of pa-
tients undergoing isolated PA reconstruction. On theTABLE 3. Historical results of reconstruction of the pulmonary artery, alone or associated with a bronchial sleeve resection
Reference Patients Complications (%) Technical complications (%) Mortality (%) Survival (% at 5 y)
Rendina et al,11 1999 52 13.4% 1.9% 0% 38.3%
Icard et al,23 1999 16 NR NR NR 39%*
Okada et al,7 2000 21 NR 0% 0% 48%*
Shrager et al,24 2000y 33 45% 0% 0% 46.7%z
Fadel et al,18 2002 11 12.4% 1.4% 0.7% 52%*
Chunwei et al,19 2003 21 NR 0% NR 33.3%*
Lausberg et al,20 2005 67 NR 0% 1.5% 42.9%*
Nagayasu et al,21 2006 29 27.6% NR 17.2% 24.2%*
Cerfolio et al,22 2007 42 26% 0% 2.3% 60%
Figures calculated from data reported in articles. NR, Not reported. *Overall survival for pulmonary artery and bronchial reconstruction. yOnly tangential resections included in this
study. zSurvival at 4 years.ardiovascular Surgery c Volume 138, Number 5 1189
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between the groups, with only a slight difference in terms
of distant recurrence. The disease-free survival did not
show a significant difference between the groups, and
a more detailed analysis showed that overall survival of
patients undergoing isolated PA reconstruction was
mainly affected by nonneoplastic events. This finding
was confirmed by univariate and multivariate analyses
of disease-free survival.
Overall, PA reconstruction in patients with NSCLC not
only is feasible and safe but yields excellent long-term sur-
vival. Our results support this technique as a viable and on-
cologically effective option for patients with NSCLC.
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Discussion
Dr Shaf Keshavjee (Toronto, Ontario, Canada). Federico, I
congratulate you and your team on an excellent report of more
than 100 sleeve resections of the PA with an operative mortality
as good as or better than most report with simple lobectomy.
First, would you discuss a little further why you think the pa-
tients with isolated PA resections did worse than those with com-
bined bronchovascular resections? The 5-year survival was
actually half.
Dr Venuta. Thank you for your comments. When this point
emerged from the statistical analysis, it really surprised us. We
were more than just surprised, we were disappointed. In fact, we
feared that this assumption would again open the door to the sup-
porters of pneumonectomy, who believe that the closer we go to
the hilum, the better we clean the lymphatic drainage and the higher
will be long-term survival. We have also, however, done a disease-
free survival analysis. That disease-free survival is NSCLC-specific
survival and shows no significant differences between the groups.
These groups show exactly the same incidences of local and distant
recurrence. The differences in overall survival between the groups
were probably related to the numbers of nonneoplastic events,
which were higher in the isolated PA reconstruction population.
Dr Keshavjee. My second question is with respect to oncologic
considerations. If you see tumor transgressing the PA wall, that is
intraluminally, are you more likely to recommend adjuvant chemo-
therapy for distant disease concerns?
Dr Venuta. Full-thickness invasion of the vascular wall with tu-
mor inside the artery was extremely rare in our experience. I can
clearly remember only 1 patient with a tumor inside the lumen.
That patient also had N1 disease and received adjuvant chemother-
apy. e believe that this is a rare event that should be addressed on
a case-by-case basis with the medical and radiation oncologists.
DrKeshavjee. Finally, in terms of your decision making, for the
patients who might get induction chemotherapy, do you operate to
resect the PA on the basis of the original CT findings, or do yourgery c November 2009
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Smake your decision to resect the PA intraoperatively on the basis of
current findings?
Dr Venuta. The original CT findings certainly give good infor-
mation about the previous extent of the disease. What we observe
on the operating table is much more important, however, and the
final decision is made on the basis of these findings.
Dr Mark Krasna (Towson, Md). Dr Venuta, excellent presen-
tation, and we owe you and Dr Rendina a debt in terms of using
this technique in our practice.
I have two specific questions. First, you talked about induction
therapy. Did any of your patients receive chemotherapy with radi-
ation and then PA resection, or were these cases induction with che-
motherapy alone?
Dr Venuta. Our standard policy is to administer induction che-
motherapy. All patients in this group received induction chemo-
therapy, with the exception of 3 who received radiotherapy.
Those 3 patients received induction radiotherapy because their dis-
ease had been judged inoperable at other institutions, and the radio-
therapy was actually administered with therapeutic intent. After our
evaluation, these cases were judged operable.
Dr Krasna. And there was no difference between those 3 and
the others?
DrVenuta. Those 3 were the 3 who underwent pneumonectomy
under CPB with patch reconstruction of the origin of the left PA.
Dr Krasna. My other question is related to another technique
that you and Dr Rendina have helped us with, which is routine
use of the intercostal muscle flap. As you know, we do that after
all chemoradiation resections. In my personal practice, I always
use the flap as a circumferential wrap when I do the bronchial
sleeve. I’m curious, if you’re doing a bronchial and arterial sleeve,
how do you actually place your intercostal flap?
Dr Venuta. The intercostal flap is always used in case of com-
bined bronchovascular reconstruction, and the flap is wrapped
around the bronchus with the technique that we have previously de-
scribed for isolated bronchial sleeve resection. In such cases, we
just pay a little more attention when we pass it between the bron-
chus and the artery.
Dr Robert J. Cerfolio (Birmingham, Ala). I congratulate you
and Dr Rendina. You talked to me about some of the finer tech-
niques of PA resection, and I took those back to Birmingham and
have been able to do them, though probably not as well as you. I
was a little disappointed that you didn’t have more of the actual sur-
gical techniques, because that is the key to this.
I have a couple of quick questions. One of the things you’ve
done is, instead of clamping the PA distally, you have movedThe Journal of Thoracic and Cthat clamp to the inferior pulmonary vein if you’re doing a left up-
per lobe vein. Are you still doing that? Your distal control of the
artery is really the vein, allowing you to have a lot of room to
work in the PA, correct?
Dr Venuta. Recently we moved to the control of the distal PA at
the hilum, if there is enough space to place the clamp. Otherwise,
we keep on clamping the inferior vein.
Dr Cerfolio. Well, I love the fact that you taught me how to
clamp the vein. It allows me to look inside the artery. It allows
me to judge whether there’s tension on the artery. Instead of work-
ing in a tiny little area in between the artery with a proximal clamp
and a distal clamp right next to it, I’ve got the whole PA wide open
and more room and better ability to judge whether I needed to
patch or do an end-to-end anastomosis. So I think that’s a great
trick.
Dr Venuta. That is obviously done when it’s possible and there
is room to place a clamp. If this is not possible, we are forced to go
down to the inferior vein.
Dr Cerfolio. Okay. The second thing is heparin. I have moved
away now to using almost no intraoperative heparin. I mean that I
will give them 500 units of heparin just to treat ‘‘the lawyers,’’ in
case there’s a clot in the PA, but I don’t know whether we really
need heparin. Are you heparinizing when you clamp your PA?
Dr Venuta. We use much less heparin than we did before. Now
we use between 1500 and 2000 units before clamping. We still
don’t reverse heparin with protamine at the end of the operation,
and these patients receive standard antithrombotic prevention
with low–molecular weight subcutaneous heparin, as do all the
other patients.
Dr Cerfolio. I’m surprised to hear you say that you wrap the
bronchus. I never circumferentially wrap the bronchus. I just put
it around the top part of the bronchus. So when I do a PA sleeve
with a sleeve of the bronchus and a sleeve of the PA, I just put
them in between. Are you really circumferentially wrapping the
bronchus or the PA, or just interposing them in between?
Dr Venuta. We wrap the bronchus with the intercostal muscle.
In our early studies, we demonstrated that intercostal wrapping con-
tributes to protecting the bronchial anastomosis and separating the
potential dehiscence from the rest of the pleural cavity, avoiding
bronchopleural or bronchoarterial fistulas. It also contributes to re-
vascularization of the bronchus, and this has been demonstrated
with arteriography.
Dr Cerfolio. So obviously since I got every question wrong and
you are doing it quite differently from me, I need some more help
and learning from you and your group. Thank you.ardiovascular Surgery c Volume 138, Number 5 1191
